Guillaume Pineton de Chambrun

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Natural History of Eosinophilic Gastroenteritis

Guillaume Pineton de Chambrun, Florent Gonzalez, Jean–Yves Canva et al. · Clinical Gastroenterology and Hepatology · 2011 · 223 citations · Full text

Medicine, Internal Medicine, Pathology +14

A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome

Guillaume Pineton de Chambrun, Christel Neut, Amélie Chau et al. · Digestive and Liver Disease · 2014 · 115 citations

Medicine, Nutritional Sciences, Pharmacology +12

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

Benjamin Pariente, Guillaume Pineton de Chambrun, Roman Krzysiek et al. · Inflammatory Bowel Diseases · 2011 · 111 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Édouard Louis, Matthieu Resche‐Rigon, David Laharie et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 108 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14